NCT00438152已完成4 期
A 24-week, Randomized, Open-label, 2-arm Study to Compare the Safety, Efficacy and Tolerability of Invirase® Tablets With Ritonavir Versus Kaletra® Tablets in HIV 1 Infected Adults on a Kaletra® Based Regimen With 2 Nucleosides/Nucleotides
Royal Free Hampstead NHS Trust1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- To evaluate the lipid benefits of Invirase® tablets with ritonavir versus Kaletra® tablets in HIV-1 infected adults on an antiretroviral regimen containing Kaletra® with two nucleosides/nucleotides
研究概览
简要总结
This study will compare the benefit for patients switching from Kaletra® to Invirase® tablets over remaining on Kaletra® (based on randomization), to elicit the lipid benefits inferred in previous studies
详细描述
This is a prospective, phase IV, multicentre, randomised, open-label, 2-arm, 24-week study. Approximately 130 HIV-1 infected patients on a stable antiretroviral regimen containing Kaletra® with 2 nucleoside/nucleotide analogues will be randomized to 1 of 2 treatment arms: saquinavir with ritonavir 1000/100 mg BID (using Invirase® tablets) or lopinavir/ritonavir 400/100 mg BID (using Kaletra® tablets).Eligibility for enrollment will be determined at a screening visit that will occur within 30 days of the baseline visit. Protocol-defined study assessments will take place at clinic visits at the end of Weeks 4, 12, and 24.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-nursing females >18 years of age
- •Seropositive for HIV-1
- •On an antiretroviral combination of Kaletra® with 2 nucleoside/nucleotide analogues for at least 6 months
- •HIV-1 RNA viral load <50 copies/mL (2 consecutive measurements in the prior 6 months) plus screening viral load <50 copies/ml.
- •Ability and willingness to provide written informed consent and adhere to the study regimen
- •Females of childbearing potential must have a documented negative serum or urine pregnancy test at screening/baseline and ensure that 2 reliable forms of contraception are being used, including a barrier method, for the duration of the study and for 90 days after the last dose of study medication
排除标准
- •Documented virological failure on a protease inhibitor ARV regimen prior to commencing Kaletra® regimen
- •Documented protease mutation (one or more from the following list) prior to commencing Kaletra® regimen:
- •M46I/L/V, I47A/V, G48V/M, I50V, F53L/Y, I54L/M/V/A/T/S, V82A/T/S/F/M/L, I84A/V/C, L90M
- •Patients with acute hepatitis B or C infection
- •Females who are pregnant, breast-feeding, or who plan to become pregnant or breast-feed during the study·
- •Significant renal dysfunction (creatinine clearance [CrCl] <60 mL/min) and/or hepatic impairment (aspartate aminotransferase/alanine aminotransferase [AST/ALT] >3 X ULN and/or documented liver cirrhosis)
- •Note: The site will calculate each patient's CrCl using the Cockcroft-Gault formula [28] as shown below:
- •CrCl = [140 - age (yr)] × weight (kg) × constant 72 × serum creatinine (Cr) (mg/dL) where, constant = 1 for men and 0.85 for women
- •Any current known clinical or laboratory parameter of ACTG Grade 4 (see Appendix 4). However, asymptomatic Grade 4 abnormalities will be permitted at the discretion of the investigator if deemed clinically appropriate. Abnormalities deemed insignificant by the investigator must be discussed with the sponsor prior to enrollment.
- •Evidence of active, untreated opportunistic infection, intercurrent illness, drug toxicity or any other condition such that in the judgment of the investigator the patient would not be able to take or continue a prescribed antiretroviral regimen
- •Malignancy requiring chemotherapy or radiotherapy
- •Known hypersensitivity to any of the prescribed antiretroviral drugs or formulation components
- •Evidence of alcohol and/or drug or substance abuse that in the judgment of the investigator would likely result in the patient being unreliable in fulfilling the conditions of the protocol
- •History of psychological illness or conditions that in the judgment of the investigator might interfere with the patient's ability to understand the requirements of the study
- •History of drug non-adherence that in the judgment of the investigator would result in the patient being unreliable in fulfilling the conditions of this protocol
- •Patients who had received an investigational new drug within the last 4 weeks
- •Currently taking, or anticipate taking during the course of the study, any drug contraindicated with the antiretroviral drugs they have been randomized to receive
研究组 & 干预措施
Invirase® tablets
Active Comparator
干预措施: Saquinavir (Invirase®) (Drug)
Kaletra® tablets
Active Comparator
干预措施: Lopinavir/ritonavir (Kaletra®) (Drug)
结局指标
主要结局
To evaluate the lipid benefits of Invirase® tablets with ritonavir versus Kaletra® tablets in HIV-1 infected adults on an antiretroviral regimen containing Kaletra® with two nucleosides/nucleotides
时间窗: 24 weeks
次要结局
- To evaluate the efficacy of Invirase® tablets with ritonavir versus Kaletra® tablets in HIV-1 infected adults on an ARV regimen containing Kaletra® with 2 nucleosides/nucleotides.(4 weeks, 12 weeks and 24 weeks.)
- To evaluate additional safety and tolerability of Invirase® tablets with ritonavir versus Kaletra® tablets in HIV-1 infected adults on an antiretroviral regimen containing Kaletra® with 2 nucleosides/nucleotides.(Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Switching From PI to RALtegravir in HIV Stable PatientsHIV InfectionsNCT00528892Hospital Clinic of Barcelona282
Unknown
4 期
Simplification From Protease Inhibitors to RaltegravirHIV InfectionsNCT00941083Hospital Carlos III, Madrid240
已完成
不适用
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infectionHuman Immunodeficiency Virus InfectionNCT01328158AbbVie (prior sponsor, Abbott)236
已完成
4 期
Safety and Efficacy of Kaletra in ARV Therapy Experienced PatientsHuman Immunodeficiency VirusNCT00648999AbbVie (prior sponsor, Abbott)207
已完成
4 期
Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ PatientsQuality of LifeHIV InfectionsNCT00274001Boehringer Ingelheim158